By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Medical Answers > How long can you stay on Herceptin and Perjeta?

How long can you stay on Herceptin and Perjeta?

Answers by TheMediTary.Com - Last updated: 12-Jul-2023

When Perjeta (generic name: pertuzumab) and Herceptin (generic name: trastuzumab) are used to treat HER2+ early breast cancer as adjuvant treatment (after surgery), this regimen may be continued every 3 weeks for one year (up to 18 cycles). You may need to stop treatment early due to side effects or if your disease returns.

When Perjeta is given as neoadjuvant therapy (before surgery for the treatment of HER2+ early breast cancer), you will receive Perjeta, Herceptin and a chemotherapy regimen every 3 weeks for 3 to 6 cycles. If you start Perjeta and Herceptin-based therapy before surgery, you may continue to get it after surgery to complete 1 year (up to a total of 18 cycles).

For treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you experience side effects from the medicine that require you to stop treatment.

What type of breast cancer does Perjeta treat?

Perjeta is a prescription medication approved by the FDA to treat HER2+ early breast cancer or metastatic breast cancer (cancer that has spread to different parts of the body). It is a member of the HER2 inhibitor drug class.

Perjeta is given with another targeted treatment called Herceptin (trastuzumab), which also targets HER2 receptors, but in a different way. You will also usually receive chemotherapy treatments during your Perjeta and Herceptin regimen.

Bottom Line

For the treatment of HER2+ early breast cancer, Perjeta treatment is usually continued for one year (up to 18 cycles) along with Herceptin treatment. These medications are given in the clinic on the same day. You will receive these medicines through your vein by an intravenous (IV) infusion. You may need to stop treatment early due to disease progression or side effects.

For treatment of HER2+ metastatic breast cancer, you will receive Perjeta and Herceptin until the medicine no longer controls your breast cancer or you experience side effects from the medicine that require you to stop treatment.

This is not all the information you need to know about Perjeta and Herceptin for safe and effective use. Review the full Perjeta information here, and Herceptin here, and discuss this information with your doctor or other health care provider.

Share this Article

Featured questions

  • How do Herceptin (trastuzumab) and Perjeta (pertuzumab) work together?
  • What is the difference between Herceptin and Herceptin Hylecta?
  • How long does Herceptin stay in your body?
  • What is the difference between Herzuma and Herceptin?
  • What happens after Herceptin treatment?
  • What are the biosimilars of Herceptin?
  • What is Herceptin? Is Herceptin a chemo drug? How does it work?
  • How effective is Herceptin for Breast & Gastric Cancer?
  • What is the difference between Ogivri and Herceptin?
  • How long can I stay on Herceptin?
  • Can these drugs be used in Thalassemia patients?
  • How does Lupron (leuprolide) work for prostate cancer?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch (Hydrocortisone topical)
Centrum Adult (Multivitamins and minerals)
Crovalimab
Cyltezo Prefilled Syringe (Adalimumab)
Zepbound Pen (Tirzepatide)
Mylanta One (Calcium carbonate, magnesium hydroxide, and simethicone)
Uretron Ds (Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate)
Medihoney Wound And Burn Dressing (Topical emollients)
Lidotrode
Libervant (Diazepam (buccal))
Moderna Covid-19 (Covid-19 (6m-11y) vaccine, moderna (2024-2025))
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by